Abstract
Naphthalimide-benzimidazole conjugates were prepared using two different types of spacer units; either a simple alkane chain or a substituted piperazine moiety with variable alkyl side chains. Each set of conjugates was evaluated for their in vitro anticancer activity, and compounds 14a, 14b and 20c were found to exhibit significant activity against a number of cancer cell lines. In particular, compound 14a showed remarkable anticancer activity with GI50 values of 0.02 μM and 0.49 μM against central nervous system (SNB-75) and leukemia (K-562) cell lines, respectively. Compound 14b showed noticeable activity against melanoma (MAME-3M) cell line with GI50 value 0.09 μM. Compound 20c also displayed selectivity against leukemia cell lines with GI50 values up to 0.21 μM as well as appreciable broad-spectrum cytotoxicity.
Keywords: Benzimidazole, conjugates, cytotoxicity, naphthalimide, piperazine.
Letters in Drug Design & Discovery
Title:Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Volume: 12 Issue: 5
Author(s): Ahmed Kamal, Pogula Praveen Kumar, Mohammed Naseer Ahmed Khan, Bobburi Naga Sheshadri and Naga Sheshadri
Affiliation:
Keywords: Benzimidazole, conjugates, cytotoxicity, naphthalimide, piperazine.
Abstract: Naphthalimide-benzimidazole conjugates were prepared using two different types of spacer units; either a simple alkane chain or a substituted piperazine moiety with variable alkyl side chains. Each set of conjugates was evaluated for their in vitro anticancer activity, and compounds 14a, 14b and 20c were found to exhibit significant activity against a number of cancer cell lines. In particular, compound 14a showed remarkable anticancer activity with GI50 values of 0.02 μM and 0.49 μM against central nervous system (SNB-75) and leukemia (K-562) cell lines, respectively. Compound 14b showed noticeable activity against melanoma (MAME-3M) cell line with GI50 value 0.09 μM. Compound 20c also displayed selectivity against leukemia cell lines with GI50 values up to 0.21 μM as well as appreciable broad-spectrum cytotoxicity.
Export Options
About this article
Cite this article as:
Kamal Ahmed, Praveen Kumar Pogula, Naseer Ahmed Khan Mohammed, Naga Sheshadri Bobburi and Sheshadri Naga, Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents, Letters in Drug Design & Discovery 2015; 12 (5) . https://dx.doi.org/10.2174/1570180811666140915221955
DOI https://dx.doi.org/10.2174/1570180811666140915221955 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Synergistic Antimicrobial Activity of Combinations of Sanguinarine and EDTA with Vancomycin Against Multidrug Resistant Bacteria
Drug Metabolism Letters Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Deep Penetration of Nanoparticulate Drug Delivery Systems into Tumors: Challenges and Solutions
Current Medicinal Chemistry Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice
Current Cancer Drug Targets Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets Pharmacogenetics, Pharmacogenomics and Epigenetics of Nrf2-regulated Xenobioticmetabolizing Enzymes and Transporters by Dietary Phytochemical and Cancer Chemoprevention
Current Drug Metabolism A Systems Biology Approach for miRNA-mRNA Expression Patterns Analysis in Rheumatoid Arthritis
Combinatorial Chemistry & High Throughput Screening Real-time Medical Visualization of Human Head and Neck Anatomy and its Applications for Dental Training and Simulation
Current Medical Imaging Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Fast Determination of β-estradiol by Chromatographic Method and its Application to Clinical Pharmacokinetics Studies
Current Pharmaceutical Analysis S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Applications of Diphenylamine and Its Derivative as Potent Bioactive Compound: A Review
Current Bioactive Compounds Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design